GlaxoSmithKline today said that it has been asked for new info on its 2013 China bribery scandal for the U.K.’s Serious Fraud Office.
South Korea’s Samsung BioLogics reported a 56% jump in sales to $420 million (KRW 459.8 billion) for 2017, which the company attributes to boosts from two of…
“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.
AstraZeneca made deals with China's Alibaba and Tencent as the British drugmaker reported double-digit growth in the country.
Mylan and Biocon win CHMP nod for a Lantus biosimilar, Takeda's Zika vaccine fast-tracked by the FDA, Celltrion got a warning letter.
The FDA has issued a warning letter for the Celltrion plant in South Korea that makes Pfizer's Remicade biosimilar, Inflectra.
An API maker in Bizen, Japan, has joined a growing list of Japanese drugmakers to be criticized by the FDA in warning letters and bans.
The Philippine DOH is now officially asking Sanofi to refund some $39 million for used Dengvaxia doses as well.
Ready to challenge GlaxoSmithKline and Merck, India's Bharat Biotech has won WHO prequalification for its rotavirus vaccine Rotavac.
Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.